Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.

doi:10.1016/j.ebiom.2017.10.015

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.

EBioMedicine - 1 Nov 2017

Niu Huifeng, Shin Hyunjin, Gao Feng, Zhang Jacob, Bahamon Brittany, Danaee Hadi, Melichar Bohuslav, Schilder Russell J, Coleman Robert L, Falchook Gerald, Adenis Antoine, Behbakht Kian, DeMichele Angela, Dees Elizabeth Claire, Perez Kimberly, Matulonis Ursula, Sawrycki Piotr, Huebner Dirk, Ecsedy Jeffrey

Abstract excerpt

BACKGROUND: Alisertib (MLN8237) is an investigational, oral, selective Aurora A kinase inhibitor. Aurora A contains two functional single nucleotide polymorphisms (SNPs; codon 31 [F/I] and codon 57 [V/I]) that lead to functional changes. This study investigated the prognostic and predictive significance of these SNPs. METHODS: This study evaluated associations between Aurora A SNPs and overall survival (OS) in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinase A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azepines

Share to Biomarkers, Tumor

Share to Disease-Free Survival

Share to Neoplasm Staging

Share to Paclitaxel

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 29122619
DOI: 10.1016/j.ebiom.2017.10.015
PMCID: PMC5704062

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.PMID 29122619Read ↗

Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib.Semantic proximity Read ↗

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A InhibitorsSemantic proximity Read ↗

Impact of Aurora Kinase A Polymorphism and Epithelial Growth Factor Receptor Mutations on the Clinicopathological Characteristics of Lung Adenocarcinoma.Semantic proximity Read ↗

Aurora Kinases as Anticancer Drug TargetsSemantic proximity Read ↗

Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer.Semantic proximity Read ↗

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.Semantic proximity Read ↗

Genetic variations in AURORA cell cycle kinases are associated with glioblastoma multiforme.Semantic proximity Read ↗

Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma.Semantic proximity Read ↗

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.Semantic proximity Read ↗

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.Semantic proximity Read ↗

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitorSemantic proximity Read ↗

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.